ANALYTICAL & LAB EQUIPMENT
This diagram demonstrates the increased speed provided by the Sola platform
THE GIBSON SOLA PLATFORM Telesis Bio describes its new Gibson SOLA platform as a ‘digital to biological converter’ that uploads sequences into proprietary software and provides a predictive success score that can be used to optimise sequences. DNA is then assembled in a mechanism that enriches for the correct molecule at each cycle and produces uniquely high-quality DNA that does not require further downstream purifi cation.
PROVIDING SCIENTISTS WITH AUTONOMY Sequences used for building the biologics are provided by the scientists, meaning they are in full control of the entire process. They can also use the resulting DNA or mRNA in any future experiments. According to Eric Esser, chief
executive of Telesis Bio, the product “allows customers to design a gene and make it in-house overnight, helping to feed their AI engine.” He continues: “The technology is fast, high-quality and fully automated, providing data that will fuel drug discovery and the ability to develop breakthrough therapies. It has also been designed to allow customers to take full control of their nucleic acid supply-chain, protect valuable intellectual property, and maintaining ownership of data and insights.
We fully expect this to have a signifi cant impact on future AI drug discovery processes and models.”
GENERATING PROPRIETARY DATA As stated, customers will be generating their own proprietary data and this can be used to gain insights and enhance future AI models. This is also a potential revenue stream for the research community. Telesis Bio claims that the platform
trains AI models 93% more quickly than if a researcher relies on outsourcing; it also creates molecules that may be very diff icult for a service provider to manufacture.
SEACHANGE IN BIOLOGICS ECOSYSTEM Esser says: “Allowing DNA and mRNA creation in house and overnight puts control of what is being built with the researcher or scientist rather than their service provider. This marks a sea change in what was traditionally a very complicated and time consuming process.”
VENTURE CAPITAL FUNDING The funding was led by Novalis LifeSciences and Northpond Ventures and will take the form of a Purchase Agreement that provides for the sale and issuance of convertible preferred stock in two closings. The
initial tranche included the sale and issuance of approximately US$17m in shares of convertible stock of which US$8m was tied to cash infusion, and US$9m was related to conversion of outstanding debt into convertible stock. Subject to the determination of the company’s board of directors to aff ect the second tranche closing on or before March 6, 2026, the second tranche is expected to include the sale and issuance of US$4m in shares of convertible preferred stock.
ABOUT NORTHPOND VENTURES Northpond Ventures is a multi-billion dollar science-driven venture capital fi rm based in the US. The fi rm is engaged in the academic ecosystem, having founded The Laboratory for Bioengineering Research and Innovation at Harvard’s Wyss Institute, The MIT-Northpond Program, and The Northpond Laboratories – Program for Research and Innovation at Stanford Medicine. Northpond Ventures has led or co-led over 60 fi nancings since it was set up in 2018 and sits on the board of the vast majority of these businesses.
For more information visit:
www.telesisbio.com
www.scientistlive.com 19
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
